Copyright
©The Author(s) 2017.
World J Rheumatol. Mar 12, 2017; 7(1): 1-7
Published online Mar 12, 2017. doi: 10.5499/wjr.v7.i1.1
Published online Mar 12, 2017. doi: 10.5499/wjr.v7.i1.1
Table 2 Our 157 physicians’ knowledge, fear and experience regarding bisphosphonates-reported side effects
| Side effects | Reported by physicians n (%) | Feared by physicians n (%) | Encountered by physicians n (%) |
| Acute phase reaction | 86 (54.8) | 12 (7.6) | 42 (26.8) |
| Atrial fibrillation | 21 (13.4) | 12 (7.6) | 0 (0.0) |
| Atypical femoral fractures | 67 (42.7) | 48 (30.6) | 13 (8.3) |
| Esophageal cancer | 18 (11.5) | 11 (7.0) | 0 (0.0) |
| Hepatotoxicity | 39 (24.8) | 18 (11.5) | 2 (1.3) |
| Hypocalcaemia | 72 (45.9) | 33 (21.0) | 27 (17.2) |
| Ocular inflammation | 12 (7.6) | 3 (1.9) | 2 (1.3) |
| Osteonecrosis of the jaw | 118 (75.2) | 93 (59.2) | 38 (24.2) |
| Renal toxicity | 84 (53.5) | 67 (42.7) | 33 (21.0) |
| Severe musculoskeletal pain | 59 (37.6) | 10 (6.4) | 24 (15.3) |
| Upper GI intolerance | 122 (77.7) | 45 (28.7) | 70 (44.6) |
| No side effect | 2 (1.3) | 7 (4.5) | 32 (20.4) |
- Citation: El Osta L, El Osta N, Tannous R, Aoun A, Ghosn M, El Osta H. Physicians’ knowledge and attitude regarding bisphosphonates-related adverse events: An observational study. World J Rheumatol 2017; 7(1): 1-7
- URL: https://www.wjgnet.com/2220-3214/full/v7/i1/1.htm
- DOI: https://dx.doi.org/10.5499/wjr.v7.i1.1